These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 18702783)

  • 1. X marks the spot for BPH therapy?
    Wyllie MG
    BJU Int; 2008 Aug; 102(3):399. PubMed ID: 18702783
    [No Abstract]   [Full Text] [Related]  

  • 2. Special Issue: Current practices in the management of benign prostatic hyperplasia. Introduction.
    Roehrborn CG; Kaplan SA
    BJU Int; 2008 Nov; 102 Suppl 2():1-2. PubMed ID: 19032602
    [No Abstract]   [Full Text] [Related]  

  • 3. Medical treatments for benign prostatic hyperplasia and sexual function.
    Giuliano F
    BJU Int; 2008 Nov; 102 Suppl 2():8-12. PubMed ID: 19032604
    [No Abstract]   [Full Text] [Related]  

  • 4. Current role of alpha-blockers in the treatment of benign prostatic hyperplasia.
    Kaplan SA
    BJU Int; 2008 Nov; 102 Suppl 2():3-7. PubMed ID: 19032603
    [No Abstract]   [Full Text] [Related]  

  • 5. Evidence-based urology in practice: composite endpoints.
    Lavallée LT; Dahm P; Breau RH
    BJU Int; 2010 Sep; 106(5):610-2. PubMed ID: 20553252
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical management of lower urinary tract symptoms with combined medical therapy.
    Roehrborn CG
    BJU Int; 2008 Nov; 102 Suppl 2():13-7. PubMed ID: 19032605
    [No Abstract]   [Full Text] [Related]  

  • 7. Editorial comment on: Is botulinum neurotoxin type A (BoNT-A) a novel therapy for lower urinary tract symptoms due to benign prostatic enlargement? A review of the literature.
    Gratzke C; Reich O
    Eur Urol; 2008 Oct; 54(4):776-7. PubMed ID: 18571304
    [No Abstract]   [Full Text] [Related]  

  • 8. Editorial comment on: Is botulinum neurotoxin type A (BoNT-A) a novel therapy for lower urinary tract symptoms due to benign prostatic enlargement? A review of the literature.
    Novara G
    Eur Urol; 2008 Oct; 54(4):775-6. PubMed ID: 18571305
    [No Abstract]   [Full Text] [Related]  

  • 9. Editorial comment.
    Noldus J
    Urology; 2011 Jan; 77(1):129-30; author reply 130. PubMed ID: 21195831
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 2-year data from the CombAT trial.
    Barkin J; Roehrborn CG; Siami P; Haillot O; Morrill B; Black L; Montorsi F;
    BJU Int; 2009 Apr; 103(7):919-26. PubMed ID: 19239460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Current role for combination therapy in male LUTS. Editorial comment].
    Carballido Rodríguez J
    Arch Esp Urol; 2010 Jun; 63(5):333-4. PubMed ID: 21149911
    [No Abstract]   [Full Text] [Related]  

  • 12. Pygeum africanum extract inhibits proliferation of human cultured prostatic fibroblasts and myofibroblasts.
    Boulbès D; Soustelle L; Costa P; Haddoum M; Bali JP; Hollande F; Magous R
    BJU Int; 2006 Nov; 98(5):1106-13. PubMed ID: 17034612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [GnRH antagonists and prostatic hyperplasia].
    Comaru-Schally AM
    Rev Prat; 2005; Spec. No():28-9. PubMed ID: 15822868
    [No Abstract]   [Full Text] [Related]  

  • 14. Relief by botulinum toxin of lower urinary tract symptoms owing to benign prostatic hyperplasia: early and long-term results.
    Brisinda G; Cadeddu F; Vanella S; Mazzeo P; Marniga G; Maria G
    Urology; 2009 Jan; 73(1):90-4. PubMed ID: 18995889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is there a rationale for the chronic use of phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia?
    Roumeguère T; Zouaoui Boudjeltia K; Hauzeur C; Schulman C; Vanhaeverbeek M; Wespes E
    BJU Int; 2009 Aug; 104(4):511-7. PubMed ID: 19239452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Editorial comment.
    Lowe FC
    Urology; 2009 Sep; 74(3):609; author reply 609-10. PubMed ID: 19716911
    [No Abstract]   [Full Text] [Related]  

  • 17. Facilitating the medical management of benign prostatic hyperplasia in primary care.
    Rees J
    BJU Int; 2010 Jan; 105(1):131-2. PubMed ID: 20132105
    [No Abstract]   [Full Text] [Related]  

  • 18. Editorial comment.
    Frauscher F; Pinggera GM
    Urology; 2011 Feb; 77(2):437-8; author reply 438. PubMed ID: 21295253
    [No Abstract]   [Full Text] [Related]  

  • 19. Ejaculatory dysfunction and its association with lower urinary tract symptoms of benign prostatic hyperplasia and BPH treatment.
    Hellstrom WJ; Giuliano F; Rosen RC
    Urology; 2009 Jul; 74(1):15-21. PubMed ID: 19428091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparison of IPSS and ICS male SF in the initial assessment of urinary disorders].
    Perrin P; Némoz C; Paparel P; Ruffion A
    Prog Urol; 2008 Sep; 18(8):519-26. PubMed ID: 18760742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.